Lunit Presents 11 Research Abstracts at the 'World's Largest' Radiology Conference

Lunit's chest X-ray image analysis solution 'Lunit Insight CXR' and mammography image analysis solution 'Lunit Insight MMG' (Photo by Lunit)

[Asia Economy Reporter Chunhee Lee] Medical artificial intelligence (AI) company Lunit announced on the 2nd that it will present 11 solo and joint research abstracts related to AI medical imaging analysis solutions at the '2022 North American Radiological Society (RSNA 2022, Radiological Society of North America 2022)' held in Chicago, USA, from the 27th of this month to the 1st of next month.

Founded in 1915 and marking its 108th session this year, RSNA is the world's largest radiology conference attended by more than 50,000 experts from academia and the medical field, as well as biotechnology company representatives worldwide. It is held annually in Chicago, USA.

Lunit will prominently present the results of a Real World Data (RWD) study applying its mammography image analysis solution, 'Lunit Insight MMG,' in actual medical settings. Unlike conventional retrospective studies conducted on past records where prescriptions have already been completed, this study is a prospective study conducted during the actual patient treatment process, attracting significant academic interest.

In addition, Lunit will present further studies related to Lunit Insight MMG, including research comparing the cancer diagnosis rates of the two-dimensional (2D) mammography image analysis solution 'Lunit Insight MMG' and the three-dimensional (3D) digital breast tomosynthesis image analysis solution 'Lunit Insight DBT,' as well as a study evaluating the AI algorithm performance (AUC) of Lunit Insight MMG on a large number of women participating in breast cancer screening programs in a specific country.

Research presentations related to the chest X-ray image analysis solution 'Lunit Insight CXR' will also be conducted. These include studies on the lung nodule detection rates between groups applied with and without Lunit Insight CXR among numerous health screening participants at domestic university hospitals, as well as studies on the respective rates of medical institutions utilizing or not utilizing Lunit Insight CXR or employing the 3D imaging analysis solution chest CT for more detailed examinations.

Furthermore, results applying the chest CT image analysis solution 'Lunit Insight Chest CT' to a large number of randomly selected patients will be presented, including research confirming the efficacy regarding changes in lung nodule intervals, a clinically important indicator, among next-generation new product studies.

Seobeomseok, CEO of Lunit, stated, "Among the 11 research abstracts presented by Lunit, 8 were selected as oral presentations representing major research achievements at RSNA 2022, confirming the changed status of medical AI research within academia." He added, "We plan to set up a solo booth at the RSNA 2022 exhibition hall to provide new customer experiences and actively engage in business networking."